Report cover image

Global Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 190 Pages
SKU # APRC20359995

Description

Summary

According to APO Research, the global Peptide-Based Vaccines for Cancer market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Peptide-Based Vaccines for Cancer market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Peptide-Based Vaccines for Cancer market include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide-Based Vaccines for Cancer, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide-Based Vaccines for Cancer, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide-Based Vaccines for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide-Based Vaccines for Cancer sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide-Based Vaccines for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide-Based Vaccines for Cancer sales, projected growth trends, production technology, application and end-user industry.

Peptide-Based Vaccines for Cancer Segment by Company

ACT
Almac
AmbioPharm
Anergis
Immatics
Immatics
Marker Therapeutics, Inc.
OncoPep
Sellas Life Sciences
Ultimovacs
Peptide-Based Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Other
Peptide-Based Vaccines for Cancer Segment by Application

Infectious Disease Prevention
Cancer Immunotherapy
Other
Peptide-Based Vaccines for Cancer Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Peptide-Based Vaccines for Cancer status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Peptide-Based Vaccines for Cancer market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Peptide-Based Vaccines for Cancer significant trends, drivers, influence factors in global and regions.
6. To analyze Peptide-Based Vaccines for Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide-Based Vaccines for Cancer market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide-Based Vaccines for Cancer industry.
Chapter 3: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Peptide-Based Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Peptide-Based Vaccines for Cancer in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
1.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume (2020-2031)
1.2.3 Global Peptide-Based Vaccines for Cancer Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Peptide-Based Vaccines for Cancer Market Dynamics
2.1 Peptide-Based Vaccines for Cancer Industry Trends
2.2 Peptide-Based Vaccines for Cancer Industry Drivers
2.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
2.4 Peptide-Based Vaccines for Cancer Industry Restraints
3 Peptide-Based Vaccines for Cancer Market by Company
3.1 Global Peptide-Based Vaccines for Cancer Company Revenue Ranking in 2024
3.2 Global Peptide-Based Vaccines for Cancer Revenue by Company (2020-2025)
3.3 Global Peptide-Based Vaccines for Cancer Sales Volume by Company (2020-2025)
3.4 Global Peptide-Based Vaccines for Cancer Average Price by Company (2020-2025)
3.5 Global Peptide-Based Vaccines for Cancer Company Ranking (2023-2025)
3.6 Global Peptide-Based Vaccines for Cancer Company Manufacturing Base and Headquarters
3.7 Global Peptide-Based Vaccines for Cancer Company Product Type and Application
3.8 Global Peptide-Based Vaccines for Cancer Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Peptide-Based Vaccines for Cancer Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Peptide-Based Vaccines for Cancer Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Peptide-Based Vaccines for Cancer Market by Type
4.1 Peptide-Based Vaccines for Cancer Type Introduction
4.1.1 Synthetic Polypeptide Vaccines
4.1.2 Recombinant Polypeptide Vaccine
4.1.3 Other
4.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Type
4.2.1 Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2020-2031)
4.2.3 Global Peptide-Based Vaccines for Cancer Sales Volume Share by Type (2020-2031)
4.3 Global Peptide-Based Vaccines for Cancer Sales Value by Type
4.3.1 Global Peptide-Based Vaccines for Cancer Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Peptide-Based Vaccines for Cancer Sales Value by Type (2020-2031)
4.3.3 Global Peptide-Based Vaccines for Cancer Sales Value Share by Type (2020-2031)
5 Peptide-Based Vaccines for Cancer Market by Application
5.1 Peptide-Based Vaccines for Cancer Application Introduction
5.1.1 Infectious Disease Prevention
5.1.2 Cancer Immunotherapy
5.1.3 Other
5.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Application
5.2.1 Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2020-2031)
5.2.3 Global Peptide-Based Vaccines for Cancer Sales Volume Share by Application (2020-2031)
5.3 Global Peptide-Based Vaccines for Cancer Sales Value by Application
5.3.1 Global Peptide-Based Vaccines for Cancer Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Peptide-Based Vaccines for Cancer Sales Value by Application (2020-2031)
5.3.3 Global Peptide-Based Vaccines for Cancer Sales Value Share by Application (2020-2031)
6 Peptide-Based Vaccines for Cancer Regional Sales and Value Analysis
6.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2020-2031)
6.2.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2020-2025
6.2.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2026-2031)
6.3 Global Peptide-Based Vaccines for Cancer Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Peptide-Based Vaccines for Cancer Sales Value by Region (2020-2031)
6.4.1 Global Peptide-Based Vaccines for Cancer Sales Value by Region: 2020-2025
6.4.2 Global Peptide-Based Vaccines for Cancer Sales Value by Region (2026-2031)
6.5 Global Peptide-Based Vaccines for Cancer Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
6.6.2 North America Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
6.7.2 Europe Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
6.8.2 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
6.9.2 South America Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value (2020-2031)
6.10.2 Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2024 VS 2031
7 Peptide-Based Vaccines for Cancer Country-level Sales and Value Analysis
7.1 Global Peptide-Based Vaccines for Cancer Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Peptide-Based Vaccines for Cancer Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Peptide-Based Vaccines for Cancer Sales by Country (2020-2031)
7.3.1 Global Peptide-Based Vaccines for Cancer Sales by Country (2020-2025)
7.3.2 Global Peptide-Based Vaccines for Cancer Sales by Country (2026-2031)
7.4 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2020-2031)
7.4.1 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2020-2025)
7.4.2 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.5.2 USA Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.6.2 Canada Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.8.2 Germany Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.9.2 France Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.9.3 France Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.11.2 Italy Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.12.2 Spain Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.13.2 Russia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.16.2 China Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.16.3 China Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.17.2 Japan Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.19.2 India Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.19.3 India Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.20.2 Australia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.24.2 Chile Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.26.2 Peru Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.28.2 Israel Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.29.2 UAE Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.31.2 Iran Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 ACT
8.1.1 ACT Comapny Information
8.1.2 ACT Business Overview
8.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
8.1.5 ACT Recent Developments
8.2 Almac
8.2.1 Almac Comapny Information
8.2.2 Almac Business Overview
8.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
8.2.5 Almac Recent Developments
8.3 AmbioPharm
8.3.1 AmbioPharm Comapny Information
8.3.2 AmbioPharm Business Overview
8.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
8.3.5 AmbioPharm Recent Developments
8.4 Anergis
8.4.1 Anergis Comapny Information
8.4.2 Anergis Business Overview
8.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
8.4.5 Anergis Recent Developments
8.5 Immatics
8.5.1 Immatics Comapny Information
8.5.2 Immatics Business Overview
8.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
8.5.5 Immatics Recent Developments
8.6 Immatics
8.6.1 Immatics Comapny Information
8.6.2 Immatics Business Overview
8.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
8.6.5 Immatics Recent Developments
8.7 Marker Therapeutics, Inc.
8.7.1 Marker Therapeutics, Inc. Comapny Information
8.7.2 Marker Therapeutics, Inc. Business Overview
8.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
8.7.5 Marker Therapeutics, Inc. Recent Developments
8.8 OncoPep
8.8.1 OncoPep Comapny Information
8.8.2 OncoPep Business Overview
8.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
8.8.5 OncoPep Recent Developments
8.9 Sellas Life Sciences
8.9.1 Sellas Life Sciences Comapny Information
8.9.2 Sellas Life Sciences Business Overview
8.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
8.9.5 Sellas Life Sciences Recent Developments
8.10 Ultimovacs
8.10.1 Ultimovacs Comapny Information
8.10.2 Ultimovacs Business Overview
8.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2020-2025)
8.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
8.10.5 Ultimovacs Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
9.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Peptide-Based Vaccines for Cancer Sales Mode & Process
9.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Peptide-Based Vaccines for Cancer Distributors
9.2.3 Peptide-Based Vaccines for Cancer Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.